nodes	percent_of_prediction	percent_of_DWPC	metapath
Fexofenadine—ABCB1—Mitomycin—urinary bladder cancer	0.198	0.256	CbGbCtD
Fexofenadine—SLCO1B3—Methotrexate—urinary bladder cancer	0.161	0.209	CbGbCtD
Fexofenadine—SLCO1A2—Methotrexate—urinary bladder cancer	0.0994	0.129	CbGbCtD
Fexofenadine—SLCO1B1—Methotrexate—urinary bladder cancer	0.0937	0.122	CbGbCtD
Fexofenadine—ABCB1—Gemcitabine—urinary bladder cancer	0.0569	0.0738	CbGbCtD
Fexofenadine—ABCB1—Cisplatin—urinary bladder cancer	0.0414	0.0536	CbGbCtD
Fexofenadine—ABCB1—Etoposide—urinary bladder cancer	0.0406	0.0527	CbGbCtD
Fexofenadine—ABCB1—Doxorubicin—urinary bladder cancer	0.0277	0.0359	CbGbCtD
Fexofenadine—ABCB1—Methotrexate—urinary bladder cancer	0.0269	0.0348	CbGbCtD
Fexofenadine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0261	0.0339	CbGbCtD
Fexofenadine—CYP2D6—urine—urinary bladder cancer	0.0025	0.105	CbGeAlD
Fexofenadine—SLCO2B1—prostate gland—urinary bladder cancer	0.0021	0.0878	CbGeAlD
Fexofenadine—SLCO1B3—vagina—urinary bladder cancer	0.00202	0.0847	CbGeAlD
Fexofenadine—SLCO1B1—renal system—urinary bladder cancer	0.00162	0.0676	CbGeAlD
Fexofenadine—SLCO2B1—renal system—urinary bladder cancer	0.00143	0.0598	CbGeAlD
Fexofenadine—SLCO1A2—renal system—urinary bladder cancer	0.00132	0.055	CbGeAlD
Fexofenadine—SLCO1B1—female reproductive system—urinary bladder cancer	0.00129	0.0542	CbGeAlD
Fexofenadine—HRH1—prostate gland—urinary bladder cancer	0.00118	0.0494	CbGeAlD
Fexofenadine—Otitis media—Epirubicin—urinary bladder cancer	0.00116	0.00617	CcSEcCtD
Fexofenadine—SLCO2B1—female reproductive system—urinary bladder cancer	0.00114	0.0479	CbGeAlD
Fexofenadine—Asthenia—Mitomycin—urinary bladder cancer	0.00114	0.00607	CcSEcCtD
Fexofenadine—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00114	0.00607	CcSEcCtD
Fexofenadine—Diarrhoea—Mitomycin—urinary bladder cancer	0.00109	0.00579	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00108	0.00575	CcSEcCtD
Fexofenadine—Otitis media—Doxorubicin—urinary bladder cancer	0.00107	0.00571	CcSEcCtD
Fexofenadine—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.00106	0.00563	CcSEcCtD
Fexofenadine—Dizziness—Mitomycin—urinary bladder cancer	0.00105	0.0056	CcSEcCtD
Fexofenadine—Vomiting—Mitomycin—urinary bladder cancer	0.00101	0.00538	CcSEcCtD
Fexofenadine—Rash—Mitomycin—urinary bladder cancer	0.001	0.00534	CcSEcCtD
Fexofenadine—Dermatitis—Mitomycin—urinary bladder cancer	0.001	0.00533	CcSEcCtD
Fexofenadine—Viral infection—Epirubicin—urinary bladder cancer	0.000998	0.00532	CcSEcCtD
Fexofenadine—Headache—Mitomycin—urinary bladder cancer	0.000995	0.0053	CcSEcCtD
Fexofenadine—Epistaxis—Fluorouracil—urinary bladder cancer	0.000977	0.00521	CcSEcCtD
Fexofenadine—Sinusitis—Fluorouracil—urinary bladder cancer	0.000972	0.00518	CcSEcCtD
Fexofenadine—Tension—Thiotepa—urinary bladder cancer	0.000961	0.00512	CcSEcCtD
Fexofenadine—Nervousness—Thiotepa—urinary bladder cancer	0.000951	0.00507	CcSEcCtD
Fexofenadine—Back pain—Thiotepa—urinary bladder cancer	0.000947	0.00504	CcSEcCtD
Fexofenadine—Nausea—Mitomycin—urinary bladder cancer	0.000944	0.00503	CcSEcCtD
Fexofenadine—Viral infection—Doxorubicin—urinary bladder cancer	0.000924	0.00492	CcSEcCtD
Fexofenadine—Vision blurred—Thiotepa—urinary bladder cancer	0.000923	0.00491	CcSEcCtD
Fexofenadine—Agitation—Thiotepa—urinary bladder cancer	0.0009	0.00479	CcSEcCtD
Fexofenadine—HRH1—epithelium—urinary bladder cancer	0.000868	0.0363	CbGeAlD
Fexofenadine—Cough—Thiotepa—urinary bladder cancer	0.000854	0.00455	CcSEcCtD
Fexofenadine—HRH1—smooth muscle tissue—urinary bladder cancer	0.000836	0.035	CbGeAlD
Fexofenadine—Myalgia—Thiotepa—urinary bladder cancer	0.000833	0.00444	CcSEcCtD
Fexofenadine—Dry eye—Epirubicin—urinary bladder cancer	0.000833	0.00444	CcSEcCtD
Fexofenadine—Flushing—Cisplatin—urinary bladder cancer	0.000818	0.00436	CcSEcCtD
Fexofenadine—Back pain—Gemcitabine—urinary bladder cancer	0.000797	0.00424	CcSEcCtD
Fexofenadine—Infection—Thiotepa—urinary bladder cancer	0.000794	0.00423	CcSEcCtD
Fexofenadine—HRH1—urethra—urinary bladder cancer	0.000791	0.0331	CbGeAlD
Fexofenadine—Tachycardia—Thiotepa—urinary bladder cancer	0.00078	0.00415	CcSEcCtD
Fexofenadine—Dry eye—Doxorubicin—urinary bladder cancer	0.000771	0.00411	CcSEcCtD
Fexofenadine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000763	0.00407	CcSEcCtD
Fexofenadine—Flatulence—Cisplatin—urinary bladder cancer	0.000756	0.00403	CcSEcCtD
Fexofenadine—Flushing—Etoposide—urinary bladder cancer	0.00075	0.00399	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000728	0.00388	CcSEcCtD
Fexofenadine—Vision blurred—Cisplatin—urinary bladder cancer	0.000723	0.00385	CcSEcCtD
Fexofenadine—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.000722	0.00384	CcSEcCtD
Fexofenadine—Cough—Gemcitabine—urinary bladder cancer	0.000719	0.00383	CcSEcCtD
Fexofenadine—Somnolence—Thiotepa—urinary bladder cancer	0.00071	0.00378	CcSEcCtD
Fexofenadine—Dyspepsia—Thiotepa—urinary bladder cancer	0.000703	0.00375	CcSEcCtD
Fexofenadine—Myalgia—Gemcitabine—urinary bladder cancer	0.000701	0.00373	CcSEcCtD
Fexofenadine—Increased appetite—Epirubicin—urinary bladder cancer	0.000697	0.00371	CcSEcCtD
Fexofenadine—Myalgia—Fluorouracil—urinary bladder cancer	0.000689	0.00367	CcSEcCtD
Fexofenadine—Fatigue—Thiotepa—urinary bladder cancer	0.000689	0.00367	CcSEcCtD
Fexofenadine—Pain—Thiotepa—urinary bladder cancer	0.000683	0.00364	CcSEcCtD
Fexofenadine—Back pain—Etoposide—urinary bladder cancer	0.00068	0.00362	CcSEcCtD
Fexofenadine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000672	0.00358	CcSEcCtD
Fexofenadine—SLCO2B1—lymph node—urinary bladder cancer	0.00067	0.028	CbGeAlD
Fexofenadine—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000668	0.00356	CcSEcCtD
Fexofenadine—Infection—Gemcitabine—urinary bladder cancer	0.000668	0.00356	CcSEcCtD
Fexofenadine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000661	0.00352	CcSEcCtD
Fexofenadine—Infection—Fluorouracil—urinary bladder cancer	0.000657	0.0035	CcSEcCtD
Fexofenadine—Pain in extremity—Epirubicin—urinary bladder cancer	0.000655	0.00349	CcSEcCtD
Fexofenadine—Myalgia—Cisplatin—urinary bladder cancer	0.000653	0.00348	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000653	0.00348	CcSEcCtD
Fexofenadine—ABCB1—prostate gland—urinary bladder cancer	0.000647	0.0271	CbGeAlD
Fexofenadine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000645	0.00344	CcSEcCtD
Fexofenadine—HRH1—female reproductive system—urinary bladder cancer	0.000645	0.027	CbGeAlD
Fexofenadine—Increased appetite—Doxorubicin—urinary bladder cancer	0.000645	0.00343	CcSEcCtD
Fexofenadine—Urticaria—Thiotepa—urinary bladder cancer	0.000635	0.00338	CcSEcCtD
Fexofenadine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000632	0.00336	CcSEcCtD
Fexofenadine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000632	0.00336	CcSEcCtD
Fexofenadine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000626	0.00334	CcSEcCtD
Fexofenadine—Infection—Cisplatin—urinary bladder cancer	0.000622	0.00332	CcSEcCtD
Fexofenadine—Cough—Etoposide—urinary bladder cancer	0.000614	0.00327	CcSEcCtD
Fexofenadine—CYP2D6—renal system—urinary bladder cancer	0.000613	0.0256	CbGeAlD
Fexofenadine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000612	0.00326	CcSEcCtD
Fexofenadine—Tachycardia—Cisplatin—urinary bladder cancer	0.000611	0.00326	CcSEcCtD
Fexofenadine—Insomnia—Gemcitabine—urinary bladder cancer	0.000608	0.00324	CcSEcCtD
Fexofenadine—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000606	0.00323	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000602	0.00321	CcSEcCtD
Fexofenadine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000599	0.00319	CcSEcCtD
Fexofenadine—Insomnia—Fluorouracil—urinary bladder cancer	0.000598	0.00318	CcSEcCtD
Fexofenadine—Somnolence—Gemcitabine—urinary bladder cancer	0.000598	0.00318	CcSEcCtD
Fexofenadine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000589	0.00314	CcSEcCtD
Fexofenadine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000589	0.00314	CcSEcCtD
Fexofenadine—Somnolence—Fluorouracil—urinary bladder cancer	0.000587	0.00313	CcSEcCtD
Fexofenadine—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000585	0.00312	CcSEcCtD
Fexofenadine—HRH1—vagina—urinary bladder cancer	0.000583	0.0244	CbGeAlD
Fexofenadine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000582	0.0031	CcSEcCtD
Fexofenadine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00058	0.00309	CcSEcCtD
Fexofenadine—Fatigue—Gemcitabine—urinary bladder cancer	0.000579	0.00309	CcSEcCtD
Fexofenadine—Pain—Gemcitabine—urinary bladder cancer	0.000575	0.00306	CcSEcCtD
Fexofenadine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000574	0.00306	CcSEcCtD
Fexofenadine—Asthenia—Thiotepa—urinary bladder cancer	0.000573	0.00305	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000571	0.00304	CcSEcCtD
Fexofenadine—Infection—Etoposide—urinary bladder cancer	0.00057	0.00304	CcSEcCtD
Fexofenadine—Pruritus—Thiotepa—urinary bladder cancer	0.000565	0.00301	CcSEcCtD
Fexofenadine—Pain—Fluorouracil—urinary bladder cancer	0.000565	0.00301	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000562	0.00299	CcSEcCtD
Fexofenadine—Tachycardia—Etoposide—urinary bladder cancer	0.00056	0.00298	CcSEcCtD
Fexofenadine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000559	0.00298	CcSEcCtD
Fexofenadine—ABCB1—seminal vesicle—urinary bladder cancer	0.000547	0.0229	CbGeAlD
Fexofenadine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000547	0.00291	CcSEcCtD
Fexofenadine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000542	0.00289	CcSEcCtD
Fexofenadine—Drowsiness—Methotrexate—urinary bladder cancer	0.000539	0.00287	CcSEcCtD
Fexofenadine—Pain—Cisplatin—urinary bladder cancer	0.000536	0.00285	CcSEcCtD
Fexofenadine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000531	0.00283	CcSEcCtD
Fexofenadine—Dizziness—Thiotepa—urinary bladder cancer	0.000528	0.00281	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000526	0.0028	CcSEcCtD
Fexofenadine—Urticaria—Fluorouracil—urinary bladder cancer	0.000525	0.0028	CcSEcCtD
Fexofenadine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000523	0.00278	CcSEcCtD
Fexofenadine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000522	0.00278	CcSEcCtD
Fexofenadine—Dyspnoea—Etoposide—urinary bladder cancer	0.000512	0.00273	CcSEcCtD
Fexofenadine—Somnolence—Etoposide—urinary bladder cancer	0.00051	0.00272	CcSEcCtD
Fexofenadine—Epistaxis—Methotrexate—urinary bladder cancer	0.000508	0.00271	CcSEcCtD
Fexofenadine—Vomiting—Thiotepa—urinary bladder cancer	0.000508	0.00271	CcSEcCtD
Fexofenadine—Drowsiness—Epirubicin—urinary bladder cancer	0.000504	0.00269	CcSEcCtD
Fexofenadine—Rash—Thiotepa—urinary bladder cancer	0.000504	0.00268	CcSEcCtD
Fexofenadine—Dermatitis—Thiotepa—urinary bladder cancer	0.000503	0.00268	CcSEcCtD
Fexofenadine—Headache—Thiotepa—urinary bladder cancer	0.000501	0.00267	CcSEcCtD
Fexofenadine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000495	0.00264	CcSEcCtD
Fexofenadine—Fatigue—Etoposide—urinary bladder cancer	0.000495	0.00264	CcSEcCtD
Fexofenadine—Pain—Etoposide—urinary bladder cancer	0.000491	0.00261	CcSEcCtD
Fexofenadine—CYP2D6—female reproductive system—urinary bladder cancer	0.000491	0.0205	CbGeAlD
Fexofenadine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000487	0.00259	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000486	0.00259	CcSEcCtD
Fexofenadine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000484	0.00258	CcSEcCtD
Fexofenadine—Asthenia—Gemcitabine—urinary bladder cancer	0.000482	0.00257	CcSEcCtD
Fexofenadine—Epistaxis—Epirubicin—urinary bladder cancer	0.000476	0.00253	CcSEcCtD
Fexofenadine—Pruritus—Gemcitabine—urinary bladder cancer	0.000476	0.00253	CcSEcCtD
Fexofenadine—ABCB1—epithelium—urinary bladder cancer	0.000475	0.0199	CbGeAlD
Fexofenadine—Nausea—Thiotepa—urinary bladder cancer	0.000475	0.00253	CcSEcCtD
Fexofenadine—Sinusitis—Epirubicin—urinary bladder cancer	0.000473	0.00252	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000469	0.0025	CcSEcCtD
Fexofenadine—Pruritus—Fluorouracil—urinary bladder cancer	0.000468	0.00249	CcSEcCtD
Fexofenadine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000467	0.00249	CcSEcCtD
Fexofenadine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000462	0.00246	CcSEcCtD
Fexofenadine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00046	0.00245	CcSEcCtD
Fexofenadine—Urticaria—Etoposide—urinary bladder cancer	0.000456	0.00243	CcSEcCtD
Fexofenadine—Abdominal pain—Etoposide—urinary bladder cancer	0.000454	0.00242	CcSEcCtD
Fexofenadine—Body temperature increased—Etoposide—urinary bladder cancer	0.000454	0.00242	CcSEcCtD
Fexofenadine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000452	0.00241	CcSEcCtD
Fexofenadine—Asthenia—Cisplatin—urinary bladder cancer	0.000449	0.00239	CcSEcCtD
Fexofenadine—ABCB1—renal system—urinary bladder cancer	0.000441	0.0184	CbGeAlD
Fexofenadine—Epistaxis—Doxorubicin—urinary bladder cancer	0.00044	0.00235	CcSEcCtD
Fexofenadine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000438	0.00233	CcSEcCtD
Fexofenadine—Dizziness—Fluorouracil—urinary bladder cancer	0.000437	0.00233	CcSEcCtD
Fexofenadine—ABCB1—urethra—urinary bladder cancer	0.000433	0.0181	CbGeAlD
Fexofenadine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000429	0.00228	CcSEcCtD
Fexofenadine—Vomiting—Gemcitabine—urinary bladder cancer	0.000427	0.00228	CcSEcCtD
Fexofenadine—Rash—Gemcitabine—urinary bladder cancer	0.000424	0.00226	CcSEcCtD
Fexofenadine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000423	0.00226	CcSEcCtD
Fexofenadine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000423	0.00225	CcSEcCtD
Fexofenadine—Headache—Gemcitabine—urinary bladder cancer	0.000421	0.00224	CcSEcCtD
Fexofenadine—Flushing—Epirubicin—urinary bladder cancer	0.00042	0.00224	CcSEcCtD
Fexofenadine—Vomiting—Fluorouracil—urinary bladder cancer	0.00042	0.00224	CcSEcCtD
Fexofenadine—Rash—Fluorouracil—urinary bladder cancer	0.000417	0.00222	CcSEcCtD
Fexofenadine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000416	0.00222	CcSEcCtD
Fexofenadine—Headache—Fluorouracil—urinary bladder cancer	0.000414	0.00221	CcSEcCtD
Fexofenadine—Asthenia—Etoposide—urinary bladder cancer	0.000412	0.00219	CcSEcCtD
Fexofenadine—Back pain—Methotrexate—urinary bladder cancer	0.000407	0.00217	CcSEcCtD
Fexofenadine—Pruritus—Etoposide—urinary bladder cancer	0.000406	0.00216	CcSEcCtD
Fexofenadine—Nausea—Gemcitabine—urinary bladder cancer	0.000399	0.00213	CcSEcCtD
Fexofenadine—Vomiting—Cisplatin—urinary bladder cancer	0.000398	0.00212	CcSEcCtD
Fexofenadine—Vision blurred—Methotrexate—urinary bladder cancer	0.000397	0.00211	CcSEcCtD
Fexofenadine—Rash—Cisplatin—urinary bladder cancer	0.000395	0.0021	CcSEcCtD
Fexofenadine—Dermatitis—Cisplatin—urinary bladder cancer	0.000395	0.0021	CcSEcCtD
Fexofenadine—Diarrhoea—Etoposide—urinary bladder cancer	0.000393	0.00209	CcSEcCtD
Fexofenadine—Nausea—Fluorouracil—urinary bladder cancer	0.000393	0.00209	CcSEcCtD
Fexofenadine—Flushing—Doxorubicin—urinary bladder cancer	0.000389	0.00207	CcSEcCtD
Fexofenadine—Flatulence—Epirubicin—urinary bladder cancer	0.000388	0.00207	CcSEcCtD
Fexofenadine—Tension—Epirubicin—urinary bladder cancer	0.000387	0.00206	CcSEcCtD
Fexofenadine—Nervousness—Epirubicin—urinary bladder cancer	0.000383	0.00204	CcSEcCtD
Fexofenadine—Back pain—Epirubicin—urinary bladder cancer	0.000381	0.00203	CcSEcCtD
Fexofenadine—Dizziness—Etoposide—urinary bladder cancer	0.00038	0.00202	CcSEcCtD
Fexofenadine—HRH1—lymph node—urinary bladder cancer	0.000377	0.0158	CbGeAlD
Fexofenadine—Nausea—Cisplatin—urinary bladder cancer	0.000372	0.00198	CcSEcCtD
Fexofenadine—Vision blurred—Epirubicin—urinary bladder cancer	0.000371	0.00198	CcSEcCtD
Fexofenadine—Cough—Methotrexate—urinary bladder cancer	0.000368	0.00196	CcSEcCtD
Fexofenadine—Vomiting—Etoposide—urinary bladder cancer	0.000365	0.00194	CcSEcCtD
Fexofenadine—Agitation—Epirubicin—urinary bladder cancer	0.000362	0.00193	CcSEcCtD
Fexofenadine—Rash—Etoposide—urinary bladder cancer	0.000362	0.00193	CcSEcCtD
Fexofenadine—Dermatitis—Etoposide—urinary bladder cancer	0.000362	0.00193	CcSEcCtD
Fexofenadine—Headache—Etoposide—urinary bladder cancer	0.00036	0.00192	CcSEcCtD
Fexofenadine—Flatulence—Doxorubicin—urinary bladder cancer	0.000359	0.00191	CcSEcCtD
Fexofenadine—Myalgia—Methotrexate—urinary bladder cancer	0.000359	0.00191	CcSEcCtD
Fexofenadine—Tension—Doxorubicin—urinary bladder cancer	0.000358	0.00191	CcSEcCtD
Fexofenadine—Nervousness—Doxorubicin—urinary bladder cancer	0.000354	0.00189	CcSEcCtD
Fexofenadine—ABCB1—female reproductive system—urinary bladder cancer	0.000353	0.0148	CbGeAlD
Fexofenadine—Back pain—Doxorubicin—urinary bladder cancer	0.000353	0.00188	CcSEcCtD
Fexofenadine—Palpitations—Epirubicin—urinary bladder cancer	0.000348	0.00186	CcSEcCtD
Fexofenadine—Cough—Epirubicin—urinary bladder cancer	0.000344	0.00183	CcSEcCtD
Fexofenadine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000344	0.00183	CcSEcCtD
Fexofenadine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000344	0.00183	CcSEcCtD
Fexofenadine—Infection—Methotrexate—urinary bladder cancer	0.000342	0.00182	CcSEcCtD
Fexofenadine—Nausea—Etoposide—urinary bladder cancer	0.000341	0.00182	CcSEcCtD
Fexofenadine—Myalgia—Epirubicin—urinary bladder cancer	0.000336	0.00179	CcSEcCtD
Fexofenadine—Agitation—Doxorubicin—urinary bladder cancer	0.000335	0.00179	CcSEcCtD
Fexofenadine—Dry mouth—Epirubicin—urinary bladder cancer	0.000328	0.00175	CcSEcCtD
Fexofenadine—Palpitations—Doxorubicin—urinary bladder cancer	0.000322	0.00172	CcSEcCtD
Fexofenadine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000322	0.00171	CcSEcCtD
Fexofenadine—Infection—Epirubicin—urinary bladder cancer	0.00032	0.0017	CcSEcCtD
Fexofenadine—ABCB1—vagina—urinary bladder cancer	0.000319	0.0134	CbGeAlD
Fexofenadine—Cough—Doxorubicin—urinary bladder cancer	0.000318	0.0017	CcSEcCtD
Fexofenadine—Tachycardia—Epirubicin—urinary bladder cancer	0.000314	0.00167	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000313	0.00167	CcSEcCtD
Fexofenadine—Insomnia—Methotrexate—urinary bladder cancer	0.000311	0.00166	CcSEcCtD
Fexofenadine—Myalgia—Doxorubicin—urinary bladder cancer	0.000311	0.00165	CcSEcCtD
Fexofenadine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000306	0.00163	CcSEcCtD
Fexofenadine—Somnolence—Methotrexate—urinary bladder cancer	0.000306	0.00163	CcSEcCtD
Fexofenadine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000304	0.00162	CcSEcCtD
Fexofenadine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000303	0.00161	CcSEcCtD
Fexofenadine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000298	0.00159	CcSEcCtD
Fexofenadine—Fatigue—Methotrexate—urinary bladder cancer	0.000296	0.00158	CcSEcCtD
Fexofenadine—Infection—Doxorubicin—urinary bladder cancer	0.000296	0.00158	CcSEcCtD
Fexofenadine—Pain—Methotrexate—urinary bladder cancer	0.000294	0.00157	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000293	0.00156	CcSEcCtD
Fexofenadine—Insomnia—Epirubicin—urinary bladder cancer	0.000291	0.00155	CcSEcCtD
Fexofenadine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000291	0.00155	CcSEcCtD
Fexofenadine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000287	0.00153	CcSEcCtD
Fexofenadine—Somnolence—Epirubicin—urinary bladder cancer	0.000286	0.00152	CcSEcCtD
Fexofenadine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000283	0.00151	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000281	0.0015	CcSEcCtD
Fexofenadine—Fatigue—Epirubicin—urinary bladder cancer	0.000277	0.00148	CcSEcCtD
Fexofenadine—Pain—Epirubicin—urinary bladder cancer	0.000275	0.00147	CcSEcCtD
Fexofenadine—Urticaria—Methotrexate—urinary bladder cancer	0.000273	0.00145	CcSEcCtD
Fexofenadine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000272	0.00145	CcSEcCtD
Fexofenadine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000272	0.00145	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000271	0.00144	CcSEcCtD
Fexofenadine—Insomnia—Doxorubicin—urinary bladder cancer	0.000269	0.00143	CcSEcCtD
Fexofenadine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000265	0.00141	CcSEcCtD
Fexofenadine—Somnolence—Doxorubicin—urinary bladder cancer	0.000265	0.00141	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000263	0.0014	CcSEcCtD
Fexofenadine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000262	0.0014	CcSEcCtD
Fexofenadine—Fatigue—Doxorubicin—urinary bladder cancer	0.000257	0.00137	CcSEcCtD
Fexofenadine—Urticaria—Epirubicin—urinary bladder cancer	0.000256	0.00136	CcSEcCtD
Fexofenadine—Pain—Doxorubicin—urinary bladder cancer	0.000255	0.00136	CcSEcCtD
Fexofenadine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000254	0.00135	CcSEcCtD
Fexofenadine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000254	0.00135	CcSEcCtD
Fexofenadine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000253	0.00135	CcSEcCtD
Fexofenadine—Asthenia—Methotrexate—urinary bladder cancer	0.000247	0.00131	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000243	0.0013	CcSEcCtD
Fexofenadine—Pruritus—Methotrexate—urinary bladder cancer	0.000243	0.0013	CcSEcCtD
Fexofenadine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000237	0.00126	CcSEcCtD
Fexofenadine—Urticaria—Doxorubicin—urinary bladder cancer	0.000236	0.00126	CcSEcCtD
Fexofenadine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000235	0.00125	CcSEcCtD
Fexofenadine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000235	0.00125	CcSEcCtD
Fexofenadine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000235	0.00125	CcSEcCtD
Fexofenadine—Asthenia—Epirubicin—urinary bladder cancer	0.000231	0.00123	CcSEcCtD
Fexofenadine—Pruritus—Epirubicin—urinary bladder cancer	0.000228	0.00121	CcSEcCtD
Fexofenadine—Dizziness—Methotrexate—urinary bladder cancer	0.000227	0.00121	CcSEcCtD
Fexofenadine—Diarrhoea—Epirubicin—urinary bladder cancer	0.00022	0.00117	CcSEcCtD
Fexofenadine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000219	0.00117	CcSEcCtD
Fexofenadine—Vomiting—Methotrexate—urinary bladder cancer	0.000219	0.00116	CcSEcCtD
Fexofenadine—Rash—Methotrexate—urinary bladder cancer	0.000217	0.00115	CcSEcCtD
Fexofenadine—Dermatitis—Methotrexate—urinary bladder cancer	0.000217	0.00115	CcSEcCtD
Fexofenadine—Headache—Methotrexate—urinary bladder cancer	0.000215	0.00115	CcSEcCtD
Fexofenadine—Asthenia—Doxorubicin—urinary bladder cancer	0.000214	0.00114	CcSEcCtD
Fexofenadine—Dizziness—Epirubicin—urinary bladder cancer	0.000213	0.00113	CcSEcCtD
Fexofenadine—Pruritus—Doxorubicin—urinary bladder cancer	0.000211	0.00112	CcSEcCtD
Fexofenadine—ABCB1—lymph node—urinary bladder cancer	0.000206	0.00864	CbGeAlD
Fexofenadine—Vomiting—Epirubicin—urinary bladder cancer	0.000205	0.00109	CcSEcCtD
Fexofenadine—Nausea—Methotrexate—urinary bladder cancer	0.000204	0.00109	CcSEcCtD
Fexofenadine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000204	0.00108	CcSEcCtD
Fexofenadine—Rash—Epirubicin—urinary bladder cancer	0.000203	0.00108	CcSEcCtD
Fexofenadine—Dermatitis—Epirubicin—urinary bladder cancer	0.000203	0.00108	CcSEcCtD
Fexofenadine—Headache—Epirubicin—urinary bladder cancer	0.000202	0.00107	CcSEcCtD
Fexofenadine—Dizziness—Doxorubicin—urinary bladder cancer	0.000197	0.00105	CcSEcCtD
Fexofenadine—Nausea—Epirubicin—urinary bladder cancer	0.000191	0.00102	CcSEcCtD
Fexofenadine—Vomiting—Doxorubicin—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Fexofenadine—Rash—Doxorubicin—urinary bladder cancer	0.000188	0.001	CcSEcCtD
Fexofenadine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000188	0.000999	CcSEcCtD
Fexofenadine—Headache—Doxorubicin—urinary bladder cancer	0.000186	0.000993	CcSEcCtD
Fexofenadine—Nausea—Doxorubicin—urinary bladder cancer	0.000177	0.000942	CcSEcCtD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	6.28e-05	0.00371	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.27e-05	0.00371	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	6.14e-05	0.00363	CbGpPWpGaD
Fexofenadine—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	6.1e-05	0.00361	CbGpPWpGaD
Fexofenadine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	6.05e-05	0.00358	CbGpPWpGaD
Fexofenadine—HRH1—IL-4 Signaling Pathway—EP300—urinary bladder cancer	6.04e-05	0.00357	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—GSTO2—urinary bladder cancer	6.04e-05	0.00357	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—NAT1—urinary bladder cancer	6.04e-05	0.00357	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.97e-05	0.00353	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.94e-05	0.00352	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—UGT2B7—urinary bladder cancer	5.53e-05	0.00327	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	5.37e-05	0.00318	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.14e-05	0.00304	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.11e-05	0.00302	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GSTZ1—urinary bladder cancer	5.01e-05	0.00296	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—CYP4B1—urinary bladder cancer	4.98e-05	0.00294	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	4.91e-05	0.0029	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	4.79e-05	0.00283	CbGpPWpGaD
Fexofenadine—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	4.76e-05	0.00282	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	4.76e-05	0.00281	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	4.76e-05	0.00281	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GSTO2—urinary bladder cancer	4.75e-05	0.00281	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—NAT1—urinary bladder cancer	4.75e-05	0.00281	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—SLC19A1—urinary bladder cancer	4.7e-05	0.00278	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.67e-05	0.00276	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—PRSS3—urinary bladder cancer	4.58e-05	0.00271	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—UGT2B7—urinary bladder cancer	4.34e-05	0.00257	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	4.34e-05	0.00257	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GSTZ1—urinary bladder cancer	4.28e-05	0.00253	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GSTO2—urinary bladder cancer	4.06e-05	0.0024	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—NAT1—urinary bladder cancer	4.06e-05	0.0024	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.04e-05	0.00239	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.99e-05	0.00236	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—CYP4B1—urinary bladder cancer	3.91e-05	0.00231	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	3.83e-05	0.00227	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—UGT2B7—urinary bladder cancer	3.71e-05	0.0022	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—SLC19A1—urinary bladder cancer	3.69e-05	0.00218	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.67e-05	0.00217	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—TYMP—urinary bladder cancer	3.66e-05	0.00217	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—PRSS3—urinary bladder cancer	3.6e-05	0.00213	CbGpPWpGaD
Fexofenadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.59e-05	0.00212	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.52e-05	0.00208	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.45e-05	0.00204	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—CYP4B1—urinary bladder cancer	3.34e-05	0.00198	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—NAT2—urinary bladder cancer	3.31e-05	0.00196	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	3.3e-05	0.00195	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.28e-05	0.00194	CbGpPWpGaD
Fexofenadine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.25e-05	0.00192	CbGpPWpGaD
Fexofenadine—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.24e-05	0.00192	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—SLC19A1—urinary bladder cancer	3.16e-05	0.00187	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.14e-05	0.00186	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.13e-05	0.00185	CbGpPWpGaD
Fexofenadine—SLCO2B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.08e-05	0.00182	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	3.08e-05	0.00182	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.05e-05	0.0018	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	3.03e-05	0.00179	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	2.99e-05	0.00177	CbGpPWpGaD
Fexofenadine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.99e-05	0.00177	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.88e-05	0.00171	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—TYMP—urinary bladder cancer	2.88e-05	0.0017	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—RRM2—urinary bladder cancer	2.86e-05	0.00169	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.76e-05	0.00163	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.65e-05	0.00157	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—HPGDS—urinary bladder cancer	2.65e-05	0.00157	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—ENO2—urinary bladder cancer	2.65e-05	0.00157	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.63e-05	0.00156	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—NAT2—urinary bladder cancer	2.6e-05	0.00154	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—GSTT1—urinary bladder cancer	2.57e-05	0.00152	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.56e-05	0.00151	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.53e-05	0.0015	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.47e-05	0.00146	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	2.46e-05	0.00146	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.4e-05	0.00142	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.36e-05	0.0014	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.34e-05	0.00139	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.33e-05	0.00138	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.32e-05	0.00137	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.28e-05	0.00135	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—RRM2—urinary bladder cancer	2.25e-05	0.00133	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	2.22e-05	0.00132	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.14e-05	0.00127	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—NQO1—urinary bladder cancer	2.13e-05	0.00126	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—ENO2—urinary bladder cancer	2.08e-05	0.00123	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—HPGDS—urinary bladder cancer	2.08e-05	0.00123	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.07e-05	0.00122	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.07e-05	0.00122	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.04e-05	0.0012	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.03e-05	0.0012	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.03e-05	0.0012	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	2.02e-05	0.0012	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GSTT1—urinary bladder cancer	2.02e-05	0.00119	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.01e-05	0.00119	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.99e-05	0.00117	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—HDAC4—urinary bladder cancer	1.95e-05	0.00115	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	1.92e-05	0.00114	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	1.92e-05	0.00113	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	1.92e-05	0.00113	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.89e-05	0.00112	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.86e-05	0.0011	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.81e-05	0.00107	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—GSTP1—urinary bladder cancer	1.78e-05	0.00105	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	1.78e-05	0.00105	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	1.78e-05	0.00105	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.77e-05	0.00105	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.75e-05	0.00104	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.73e-05	0.00102	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.73e-05	0.00102	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	1.72e-05	0.00102	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.72e-05	0.00102	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	1.71e-05	0.00101	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.71e-05	0.00101	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.7e-05	0.001	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—NQO1—urinary bladder cancer	1.68e-05	0.000992	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.67e-05	0.00099	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.67e-05	0.000986	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—TYMS—urinary bladder cancer	1.65e-05	0.000979	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—NCOR1—urinary bladder cancer	1.64e-05	0.000967	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—GSTM1—urinary bladder cancer	1.64e-05	0.000967	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—GLI1—urinary bladder cancer	1.63e-05	0.000966	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.63e-05	0.000962	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.61e-05	0.000955	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	1.61e-05	0.000953	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.58e-05	0.000935	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.58e-05	0.000933	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	1.57e-05	0.000926	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.54e-05	0.000911	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	1.54e-05	0.000909	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.51e-05	0.000891	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.49e-05	0.000881	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.46e-05	0.000862	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.45e-05	0.00086	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.45e-05	0.000859	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	1.45e-05	0.000855	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	1.43e-05	0.000848	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.42e-05	0.000839	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GSTP1—urinary bladder cancer	1.4e-05	0.000827	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.39e-05	0.000823	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.39e-05	0.00082	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	1.37e-05	0.00081	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.35e-05	0.0008	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.35e-05	0.000798	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	1.32e-05	0.000778	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—TYMS—urinary bladder cancer	1.3e-05	0.000769	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	1.28e-05	0.00076	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	1.28e-05	0.00076	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.23e-05	0.000728	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	1.23e-05	0.000728	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.21e-05	0.000718	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.21e-05	0.000715	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	0.000715	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.2e-05	0.000707	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.18e-05	0.000699	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	1.17e-05	0.000693	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.16e-05	0.000686	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.16e-05	0.000684	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000672	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	0.000666	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.13e-05	0.000666	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	1.12e-05	0.000662	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.12e-05	0.000661	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.11e-05	0.000659	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.11e-05	0.000658	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.1e-05	0.00065	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.1e-05	0.00065	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	1.05e-05	0.000623	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.05e-05	0.000622	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.05e-05	0.000621	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.03e-05	0.000611	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	1e-05	0.000593	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	9.92e-06	0.000587	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	9.71e-06	0.000574	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—RRM2—urinary bladder cancer	9.61e-06	0.000569	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	9.22e-06	0.000545	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	9.21e-06	0.000545	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	9.06e-06	0.000536	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—ENO2—urinary bladder cancer	8.9e-06	0.000527	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	8.9e-06	0.000527	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	8.84e-06	0.000523	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	8.63e-06	0.000511	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	8.47e-06	0.000501	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	8.39e-06	0.000496	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	8.39e-06	0.000496	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	8.14e-06	0.000481	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	8.11e-06	0.00048	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.08e-06	0.000478	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	8.04e-06	0.000476	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	7.87e-06	0.000466	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	7.69e-06	0.000455	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—EP300—urinary bladder cancer	7.67e-06	0.000454	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	7.56e-06	0.000447	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.43e-06	0.00044	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	7.29e-06	0.000432	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	7.24e-06	0.000428	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—NQO1—urinary bladder cancer	7.18e-06	0.000425	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	7.11e-06	0.00042	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	6.76e-06	0.0004	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	6.75e-06	0.000399	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	6.45e-06	0.000382	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	6.43e-06	0.00038	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	6.32e-06	0.000374	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	6.19e-06	0.000366	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—EP300—urinary bladder cancer	6.02e-06	0.000356	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.99e-06	0.000354	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	5.9e-06	0.000349	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	5.73e-06	0.000339	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	5.64e-06	0.000334	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.56e-06	0.000329	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.5e-06	0.000325	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.5e-06	0.000325	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	5.4e-06	0.00032	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.27e-06	0.000312	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	5.24e-06	0.00031	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	5.18e-06	0.000307	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	5.18e-06	0.000307	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.17e-06	0.000306	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—EP300—urinary bladder cancer	5.15e-06	0.000305	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	5.02e-06	0.000297	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.96e-06	0.000294	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	4.96e-06	0.000293	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	4.93e-06	0.000292	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.87e-06	0.000288	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.86e-06	0.000288	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	4.66e-06	0.000276	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.58e-06	0.000271	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	4.54e-06	0.000269	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	4.21e-06	0.000249	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	3.99e-06	0.000236	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	3.96e-06	0.000234	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.94e-06	0.000233	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	3.81e-06	0.000225	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.79e-06	0.000224	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	3.72e-06	0.00022	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.71e-06	0.00022	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	3.61e-06	0.000213	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	3.59e-06	0.000213	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	3.59e-06	0.000212	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.57e-06	0.000211	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	3.42e-06	0.000202	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	3.33e-06	0.000197	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.1e-06	0.000183	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	2.98e-06	0.000176	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.92e-06	0.000173	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	2.92e-06	0.000172	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	2.75e-06	0.000163	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.7e-06	0.00016	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—EP300—urinary bladder cancer	2.58e-06	0.000153	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.55e-06	0.000151	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	2.45e-06	0.000145	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.43e-06	0.000144	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	2.34e-06	0.000138	CbGpPWpGaD
